Fig. 3From: PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trialsForest plot of aggregated data representing the risk ratios of Grade 3 ≤ adverse events in recurrent OC. OC-ovarian cancer, PARPi-poly ADP ribose polymerase inhibitor, MDS / AML- myelodysplastic syndrome or acute myeloid leukemia, CI-confidential intervalBack to article page